Related Research Articles
José Baselga is a Spanish medical oncologist and researcher focused on the development of novel molecular targeted agents, with a special emphasis in breast cancer. Baselga served as Physician-in-Chief at the Memorial Sloan Kettering Cancer Center until his resignation in September 2018 after it was reported that he had failed to disclose millions of dollars in financial ties with pharmaceutical companies in his research. On January 7, 2019, AstraZeneca announced that they had hired him as head of research and development in oncology.
Van Andel Institute(VAI) is a 501(c)(3) nonprofit biomedical research and science education organization in Grand Rapids, Michigan. VAI was founded by Jay and Betty Van Andel in 1996 and comprises four divisions: Van Andel Research Institute (VARI), Van Andel Education Institute (VAEI), Van Andel Institute Graduate School (VAIGS), and Purple Community.
Stand Up To Cancer (SU2C) is a charitable program of the Entertainment Industry Foundation (EIF). SU2C aims to raise significant funds for translational cancer research through online and televised efforts. Central to the program is a telethon that was first televised by four major broadcast networks in over 170 countries on September 5, 2008. SU2C raised over $100 million after that evening's broadcast. Funds collected by Stand Up To Cancer are then distributed by the American Association for Cancer Research.
Graham Andrew Colditz MD, DrPH is an Australian chronic disease epidemiologist. He is the inaugural Niess-Gain Professor at Washington University School of Medicine, where he is Associate Director for Prevention and Control at the Alvin J. Siteman Cancer Center. He directs the Master of Population Health Science at Washington University School of Medicine. During medical training he was excited by the potential for prevention of chronic diseases. With encouragement from mentors he pursued training in the USA as it was routine for academics in Australia to obtain overseas training at that time. He is internationally recognized for leadership in cancer prevention, and is often interviewed by media for input on this topic. With members of Cancer Prevention and Control at Siteman, he blogs on issues relating to cancer prevention and screening. According to Google Scholar statistics, Colditz has the highest h-index of any living author, second only to Michel Foucault.
Charles L. Sawyers is a Howard Hughes Medical Institute (HHMI) investigator who holds the Marie-Josée and Henry R. Kravis Chair of the Human Oncology and Pathogenesis Program (HOPP) at Memorial Sloan Kettering Cancer Center (MSK). HOPP is a program created in 2006 that comprises researchers from many disciplines to bridge clinical and laboratory discoveries.
William G. Kaelin Jr. is an American Nobel Laureate physician-scientist. He is a professor of medicine at Harvard University and the Dana-Farber Cancer Institute. His laboratory studies tumor suppressor proteins. In 2016, Kaelin received the Albert Lasker Award for Basic Medical Research and the AACR Princess Takamatsu Award. He also won the Nobel Prize in Physiology or Medicine in 2019 along with Peter J. Ratcliffe and Gregg L. Semenza.
Michael A. Caliguiri is the president of City of Hope National Medical Center and the physician-in-chief. He was elected president of the American Association for Cancer Research for 2016–2017.
David M. Livingston is the Deputy Director of the Dana-Farber/Harvard Cancer Center, Emil Frei Professor of Genetics and Medicine at Harvard Medical School, Chairman of the Executive Committee for Research at Dana-Farber Cancer Institute. Dr. Livingston joined the Harvard faculty in 1973. His research focuses on breast and ovarian cancer.
Carlos L. Arteaga is the Associate Director for Clinical Research, director of the Center for Cancer Targeted Therapies, and professor of Cancer Biology and Medicine at Vanderbilt-Ingram Cancer Center. In 2014–2015, he was the president of the American Association for Cancer Research.
Gordon B. Mills is the Wayne and Julie Drinkward Endowed Chair in Precision Oncology, Director of Precision Oncology, Director of SMMART Trials and Professor in Cell, Development and Cancer Biology in the Knight Cancer Institute at Oregon Health Sciences University.
Donald Straley Coffey was the Catherine Iola and J. Smith Michael distinguished professor of urology at Johns Hopkins University School of Medicine and subsequently professor emeritus. He had a primary appointment in urology and secondary appointments in oncology, pharmacology and pathology.
Daniel D. Von Hoff is the physician in chief and director of translational research at Translational Genomics Research Institute (TGen). He is also a professor of medicine at the Mayo Clinic and medical director of research as well as chief scientific officer at US Oncology. He is most notable for his work in targeted therapies for the treatment of cancer. He led the development of gemcitabine, and has several drugs in development.
Curtis. C. Harris is the head of the Molecular Genetics and Carcinogenesis Section and chief of the Laboratory of Human Carcinogenesis at the Center for Cancer Research of the National Cancer Institute, NIH.
Bruce Allan Chabner is a professor of medicine at Harvard Medical School and Director of Clinical Research at the MGH Cancer Center at Massachusetts General Hospital. His research focuses on anti-folate drugs for the treatment of cancer.
Elizabeth M. Jaffee is an American oncologist specializing in pancreatic cancer and immunotherapy.
Nita Ahuja is a surgeon and the Chair of the Department of Surgery at Yale School of Medicine and Surgeon-in-Chief of Surgery at Yale New Haven Hospital. She is the first woman ever to serve as Chair of Surgery in Yale in its >200 year history. Before taking this position she was the first woman ever to be the Chief of Surgical Oncology at Johns Hopkins Hospital, Baltimore, USA. Ahuja researches in the field of epigenetics. She also served as the director of Sarcoma and peritoneal surface malignancy program. She is a surgeon-scientist and her research has been cited more than 11,000 times in scientific literature.
Louis Michael Staudt is a scientist at the National Cancer Institute, where he is co-chief of the Lymphoid Malignancies Branch and the director of the Center for Cancer Genomics.
Guillermina 'Gigi' Lozano is an American geneticist. She is a professor at University of Texas MD Anderson Cancer Center. Lozano is recognised for her studies of the p53 tumour suppressor pathway, characterising the protein as a regulator of gene expression.
Judy Ellen Garber is the director of the Center for Cancer Genetics and Prevention at the Dana-Farber Cancer Institute and a professor of medicine at Harvard Medical School. Garber previously served as president of the American Association for Cancer Research.
Kornelia Polyak is a professor of medicine at Harvard Medical School and an internationally recognized breast cancer expert.
References
- ↑ "Stephen B. Baylin, M.D." hopkinsmedicine.org. Retrieved 2016-12-25.
- 1 2 3 "An Epi Phenomenon | The Scientist Magazine". web.archive.org. Archived from the original on 2016-12-25. Retrieved 2016-12-25.
- ↑ "Stand Up To Cancer — Stephen B. Baylin, M.D." standup2cancer.org. Retrieved 2016-12-25.
- ↑ "Stephen Bruce Baylin, MD | Johns Hopkins - Institute of Genetic Medicine". igm.jhmi.edu. Retrieved 2016-12-25.
- ↑ "VARI-SU2C Epigenetics Dream Team Lead Investigator Bio - VARI-SU2C Epigenetics Dream Team". varisu2cepigeneticsdreamteam.vai.org. Retrieved 2016-12-25.
